<DOC>
	<DOCNO>NCT00116467</DOCNO>
	<brief_summary>The purpose study evaluate clinical laboratory safety associate administration GVAX leukemia vaccine determine feasibility generation GVAX leukemia vaccine subject acute myelogenous leukemia ( AML ) .</brief_summary>
	<brief_title>Vaccination Peripheral Stem Cell Transplant Setting Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Initial diagnosis de novo AML preexist hematologic dysplasia 3 month . No prior therapy except leukapheresis le 72 hour hydroxyurea . Prior myelodysplastic disorder , treatmentrelated leukemia . Prior myeloproliferative disease . Acute promyelocytic leukemia ( APL ) . Prior chemotherapy malignant nonmalignant disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>GVAX</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Autologous</keyword>
</DOC>